Literature DB >> 31356196

Lactate dehydrogenase and serum tumor markers for predicting metastatic status in geriatric patients with lung adenocarcinoma.

Xiaolu Ren1,2, Yixun Zhang2, Yi Lyu3, Baoli Jin2, Hongxia Guo4, Jing Wu2, Xiaomin Li2, Xuejun Liu1,3.   

Abstract

BACKGROUND: No tumor biomarker (TM) is available for de novo metastatic lung adenocarcinoma.
OBJECTIVE: To examine the serum levels of carcinoembryonic antigen (CEA), cytokeratin-19 fragments (CYFRA21-1), neuron-specific enolase (NSE), carbohydrate antigen (CA) 19-9, CA125, tissue polypeptide antigen (TPA), tissue polypeptide specific antigen (TPS), and lactate dehydrogenase (LDH) to predict de novo metastatic lung adenocarcinoma.
METHODS: This was a retrospective study of geriatric (⩾ 60 years of age) patients with lung cancer diagnosed at Shanxi Cancer Hospital from 02/2012 to 12/2017. CEA, CYFRA21-1, CA199, NSE, CA125, TPA, and TPS were detected by ELISA and LDH was detected by LDH kit. Their predictive value was assessed using receiver operating characteristic (ROC) curves and multivariable logistic regression.
RESULTS: The positive rates of LDH and TMs were higher in the metastatic group (all P< 0.05). The best single TMs were CYFRA21-1 (70.5% sensitivity) and CA199 (92.0% specificity). When using any two, the best were CYFRA21-1+TPA (77.1% sensitivity) and CA199+TPA or NSE (both 84.1% specificity). High LDH and CA125 statuses were each independently associated with brain, bone, liver, and lung metastases (all P< 0.05).
CONCLUSIONS: Abnormal level of LDH and TMs, alone or in combination, had predictive value for metastasis in geriatric patients with lung adenocarcinoma; these indicators were also associated with the metastatic site.

Entities:  

Keywords:  Lung adenocarcinoma; elderly; lactate dehydrogenase; metastasis; tumor marker

Mesh:

Substances:

Year:  2019        PMID: 31356196     DOI: 10.3233/CBM-190201

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  7 in total

1.  Exosomes in malignant pleural effusion from lung cancer patients impaired the cytotoxicity of double-negative T cells.

Authors:  Jingjing Wu; Ranran Zhu; Zhengxia Wang; Xueqin Chen; Tingting Xu; Yanan Liu; Meijuan Song; Jingxian Jiang; Qiyun Ma; Zhongqi Chen; Yuan Liu; Xiaoyue Wang; Mingshun Zhang; Mao Huang; Ningfei Ji
Journal:  Transl Oncol       Date:  2022-10-14       Impact factor: 4.803

2.  Inflammatory Marker Predicts Outcome of Oral Squamous Cell Carcinoma Receiving Chemo-Radiotherapy.

Authors:  Wei Sun; Meng Gao; Guangyuan Hu; Xun Yuan
Journal:  Cancer Manag Res       Date:  2020-12-01       Impact factor: 3.989

3.  Combining Lactate Dehydrogenase and Fibrinogen: Potential Factors to Predict Therapeutic Efficacy and Prognosis of Patients with Small-Cell Lung Cancer.

Authors:  Wen Huang; Ping Liu; Min Zong; Qian-Qian Chen; Hong Zhou; Hui Kong; Wei-Ping Xie
Journal:  Cancer Manag Res       Date:  2021-05-31       Impact factor: 3.989

Review 4.  Carbohydrate antigen 19-9 - tumor marker: Past, present, and future.

Authors:  Tsinrong Lee; Thomas Zheng Jie Teng; Vishal G Shelat
Journal:  World J Gastrointest Surg       Date:  2020-12-27

5.  Lymphocyte percentage as a valuable predictor of prognosis in lung cancer.

Authors:  Hong Huang; Lei Li; Wenxin Luo; Yongfeng Yang; Yinyun Ni; Tingting Song; Yihan Zhu; Ying Yang; Li Zhang
Journal:  J Cell Mol Med       Date:  2022-02-05       Impact factor: 5.310

6.  Elevated lactate dehydrogenase predicts poor prognosis of acute ischemic stroke.

Authors:  Xia-Xia Jin; Mei-Dan Fang; Ling-Ling Hu; Yuan Yuan; Jiu-Fei Xu; Guo-Guang Lu; Tao Li
Journal:  PLoS One       Date:  2022-10-07       Impact factor: 3.752

7.  A nomogram to predict the overall survival of patients with symptomatic extensive-stage small cell lung cancer treated with thoracic radiotherapy.

Authors:  Xun Yuan; Zhiqin Zheng; Fangfang Liu; Yuan Gao; Wenhui Zhang; Rossana Berardi; Pranshu Mohindra; Zhengfei Zhu; Jie Lin; Qian Chu
Journal:  Transl Lung Cancer Res       Date:  2021-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.